A study in Diabetes Care found that patients with breast or prostate cancer who also have type 2 diabetes face lower survival rates compared with those who do not have diabetes. Researchers also found that those who take sulfonylureas or insulin alone have a higher mortality rate and those who have metformin-only treatment have a lower mortality rate compared with patients without diabetes.

Related Summaries